GlassScriptPhysician profile
Sindu Iska
NPI 1013478718
$687.98
in general payments reported to CMS, 2019-2025
14 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.05 · 2022: $121 · 2023: $313 · 2024: $93.95 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462 · Education: $93.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $462.45 |
| Education | $93.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $218.95 | 2024-2025 | Ultomiris, Soliris |
| Janssen Biotech, INC. | $114.30 | 2023 | Tecvayli, Darzalex, Carvykti |
| Jazz Pharmaceuticals INC. | $94.87 | 2023 | |
| Lilly USA, LLC | $46.53 | 2022-2023 | Retevmo, Verzenio, Jaypirca |
| Pfizer INC. | $37.45 | 2023 | |
| Merck Sharp & Dohme LLC | $33.14 | 2022 | |
| Caris Mpi, INC. | $24.80 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $22.50 | 2023 | Orserdu |
| Emd Serono, INC. | $20.58 | 2022 | |
| Novo Nordisk INC | $18.63 | 2022 | |
| Puma Biotechnology, INC. | $17.08 | 2023 | |
| Sobi, INC | $14.53 | 2022 | |
| Daiichi Sankyo INC. | $13.57 | 2023 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sindu Iska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.